Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold) and Lilly (Silver).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ASCO 2016 | Targeted therapies for CLL: new data and unanswered questions

Jennifer Brown • 3 Jun 2016
ASCO 2016
Chronic Lymphocytic Leukemia Ibrutinib Idelalisib

Jennifer Brown, MD, PhD from the Dana-Farber Cancer Institute, Boston, MA gives an overview of her talk on targeted therapy in chronic lymphocytic leukemia (CLL) held at the American Society of Oncology (ASCO) 2016 Annual Meeting in Chicago, IL. Dr Brown adresses unanswered questions such as how to salvage patients who relapse on the BTK inhibitor ibrutinib and how to optimize the management of toxicities some patients experience. Dr Brown further discusses the issues around the trial of the PI-3 kinase inhibitor idelalisib, in particular infections in the setting of neutropenia.

More from Jennifer Brown

Genomic predictors of outcomes in CLL: insights from the SEQUOIA and ALPINE trials
1:24
Genomic predictors of outcomes in CLL: insights from the SEQUOIA and ALPINE trials
Jennifer Brown • 6 Mar 2026
The multiclonal nature of CLL and its role in resistance and relapse
1:16
The multiclonal nature of CLL and its role in resistance and relapse
Jennifer Brown • 13 Mar 2026
Treatment sequencing for patients with CLL who relapse after covalent BTKi
1:19
Treatment sequencing for patients with CLL who relapse after covalent BTKi
Jennifer Brown • 13 Mar 2026
Complex karyotype, but not isolated TP53 mutation, predicts OS in CLL in the era of targeted therapy
1:44
Complex karyotype, but not isolated TP53 mutation, predicts OS in CLL in the era of targeted therapy
Jennifer Brown • 10 Dec 2024

Related Videos

Unmet needs in CLL genomics: heterogeneity and clinical impact
1:11
Unmet needs in CLL genomics: heterogeneity and clinical impact
Elias Campo • 16 Oct 2026
Insights into key topics most likely to impact day-to-day CLL management
1:40
Insights into key topics most likely to impact day-to-day CLL management
Alessandra Ferrajoli • 16 Oct 2026
Translating current CLL evidence into national guidelines: which gaps remain?
3:33
Translating current CLL evidence into national guidelines: which gaps remain?
Mary Ann Anderson • 16 Oct 2026
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
2:40
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
Philip Thompson • 22 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals